nsc 3852 has been researched along with Acute Myelogenous Leukemia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bartels, M; Coffer, PJ; Egan, DA; Govers, AMAP; Lelieveld, D; Sonneveld, E; Wiggers, CRM; Zwaan, CM | 1 |
1 other study(ies) available for nsc 3852 and Acute Myelogenous Leukemia
Article | Year |
---|---|
Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Topics: Apoptosis; Cell Proliferation; Child; Down Syndrome; Drug Screening Assays, Antitumor; Epigenesis, Genetic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyquinolines; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Leukemoid Reaction; Nitroso Compounds; Prognosis; Tumor Cells, Cultured | 2019 |